A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.

Barrington P, Chien JY, Showalter HD, Schneck K, Cui S, Tibaldi F, Ellis B, Hardy TA

Diabetes, obesity & metabolism19 Jan 2011Cited by 91 (Europe PMC)

PMID21251178DOI10.1111/j.1463-1326.2011.01364.xPepBankPUB-21251178

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, LY reduced fasting plasma glucose at doses ≥1 mg.
In plain wordsIn patients with type 2 diabetes, LY reduced fasting blood glucose at doses ≥1 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFasting plasma glucose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
>=1 mg once weekly · 5 weeksAs given in this study (human).
Source sentences
Summary
Once-weekly administration of LY significantly reduced (p < 0.01) fasting plasma glucose, 2-h post-test meal postprandial glucose and area under the curve (AUC) of glucose after test meals at doses ≥1 mg.
3 context sentences(design, population, supporting numbers)
Summary · context
These effects were seen after the first dose and were sustained through the weekly dosing cycle.
Summary · context
This was a placebo-controlled, parallel-group, subject- and investigator-blind study of LY in subjects (N = 43) with type 2 diabetes mellitus controlled with diet and exercise alone or with a single oral antidiabetic medication.
Summary · context
Subjects received five once-weekly doses of 0.05, 0.3, 1, 3, 5 or 8 mg.
Report a problemFND-2125117801
02HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, LY reduced glucose two hours after test meals at doses ≥1 mg.
In plain wordsIn patients with type 2 diabetes, LY reduced blood glucose after meals at doses ≥1 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePostprandial glucose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
>=1 mg once weekly · 5 weeksAs given in this study (human).
Source sentences
Summary
Once-weekly administration of LY significantly reduced (p < 0.01) fasting plasma glucose, 2-h post-test meal postprandial glucose and area under the curve (AUC) of glucose after test meals at doses ≥1 mg.
3 context sentences(design, population, supporting numbers)
Summary · context
These effects were seen after the first dose and were sustained through the weekly dosing cycle.
Summary · context
This was a placebo-controlled, parallel-group, subject- and investigator-blind study of LY in subjects (N = 43) with type 2 diabetes mellitus controlled with diet and exercise alone or with a single oral antidiabetic medication.
Summary · context
Subjects received five once-weekly doses of 0.05, 0.3, 1, 3, 5 or 8 mg.
Report a problemFND-2125117802
03HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, LY reduced glucose AUC after test meals at doses ≥1 mg.
In plain wordsIn patients with type 2 diabetes, LY reduced total blood glucose exposure after meals at doses ≥1 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePost-meal glucose AUC
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
>=1 mg once weekly · 5 weeksAs given in this study (human).
Source sentences
Summary
Once-weekly administration of LY significantly reduced (p < 0.01) fasting plasma glucose, 2-h post-test meal postprandial glucose and area under the curve (AUC) of glucose after test meals at doses ≥1 mg.
3 context sentences(design, population, supporting numbers)
Summary · context
These effects were seen after the first dose and were sustained through the weekly dosing cycle.
Summary · context
This was a placebo-controlled, parallel-group, subject- and investigator-blind study of LY in subjects (N = 43) with type 2 diabetes mellitus controlled with diet and exercise alone or with a single oral antidiabetic medication.
Summary · context
Subjects received five once-weekly doses of 0.05, 0.3, 1, 3, 5 or 8 mg.
Report a problemFND-2125117803
04HumanNon-randomized trialMechanism
In patients with type 2 diabetes, most LY doses significantly increased insulin AUC normalized for glucose AUC.
In plain wordsIn patients with type 2 diabetes, most LY doses increased insulin exposure relative to glucose exposure.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseGlucose-normalized insulin AUC
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 5 weeksAs given in this study (human).
Source sentences
Summary
Most doses produced statistically significant increases in insulin and C-peptide AUC when normalized for glucose AUC.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a placebo-controlled, parallel-group, subject- and investigator-blind study of LY in subjects (N = 43) with type 2 diabetes mellitus controlled with diet and exercise alone or with a single oral antidiabetic medication.
Summary · context
Subjects received five once-weekly doses of 0.05, 0.3, 1, 3, 5 or 8 mg.
Report a problemFND-2125117804
05HumanNon-randomized trialMechanism
In patients with type 2 diabetes, most LY doses significantly increased C-peptide AUC normalized for glucose AUC.
In plain wordsIn patients with type 2 diabetes, most LY doses increased C-peptide exposure relative to glucose exposure.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseGlucose-normalized C-peptide AUC
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.05, 0.3, 1, 3, 5 or 8 mg once weekly · 5 weeksAs given in this study (human).
Source sentences
Summary
Most doses produced statistically significant increases in insulin and C-peptide AUC when normalized for glucose AUC.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a placebo-controlled, parallel-group, subject- and investigator-blind study of LY in subjects (N = 43) with type 2 diabetes mellitus controlled with diet and exercise alone or with a single oral antidiabetic medication.
Summary · context
Subjects received five once-weekly doses of 0.05, 0.3, 1, 3, 5 or 8 mg.
Report a problemFND-2125117805
06HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, all LY dose groups except 0.3 mg showed significant HBA1c reductions.
In plain wordsIn patients with type 2 diabetes, all LY dose groups except 0.3 mg showed significant reductions in long-term blood sugar.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.05, 1, 3, 5 or 8 mg once weekly · 5 weeksAs given in this study (human).
Source sentences
Summary
Statistically significant reductions in HBA1c were observed for all dose groups except 0.3 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a placebo-controlled, parallel-group, subject- and investigator-blind study of LY in subjects (N = 43) with type 2 diabetes mellitus controlled with diet and exercise alone or with a single oral antidiabetic medication.
Summary · context
Subjects received five once-weekly doses of 0.05, 0.3, 1, 3, 5 or 8 mg.
Report a problemFND-2125117806
07HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, LY 0.3 mg did not significantly reduce HBA1c.
In plain wordsIn patients with type 2 diabetes, LY 0.3 mg did not significantly reduce long-term blood sugar.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHbA1c at 0.3 mg
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3 mg once weekly · 5 weeksAs given in this study (human).
Source sentences
Summary
Statistically significant reductions in HBA1c were observed for all dose groups except 0.3 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a placebo-controlled, parallel-group, subject- and investigator-blind study of LY in subjects (N = 43) with type 2 diabetes mellitus controlled with diet and exercise alone or with a single oral antidiabetic medication.
Summary · context
Subjects received five once-weekly doses of 0.05, 0.3, 1, 3, 5 or 8 mg.
Report a problemFND-2125117807

Studies that did not test the peptide alone4

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

08HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialSafety outcome
In a placebo-controlled study of LY in patients with type 2 diabetes, nausea was among the most commonly reported adverse effects, with 35 events.
In plain wordsIn a study of LY in people with type 2 diabetes, 35 nausea events were reported.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableNausea
Study
n = 43
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Nausea events
35 events
all reported events in the study
Source sentences
Summary
The most commonly reported adverse effects (AEs) were nausea (35 events), headache (20 events), vomiting (18 events) and diarrhoea (8 events).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a placebo-controlled, parallel-group, subject- and investigator-blind study of LY in subjects (N = 43) with type 2 diabetes mellitus controlled with diet and exercise alone or with a single oral antidiabetic medication.
Summary · context
Subjects received five once-weekly doses of 0.05, 0.3, 1, 3, 5 or 8 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2125117808
09HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialSafety outcome
In a placebo-controlled study of LY in patients with type 2 diabetes, headache was among the most commonly reported adverse effects, with 20 events.
In plain wordsIn a study of LY in people with type 2 diabetes, 20 headache events were reported.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHeadache
Study
n = 43
Outcome group
Adverse events · Nervous system and cognition
Measurements
Headache events
20 events
all reported events in the study
Source sentences
Summary
The most commonly reported adverse effects (AEs) were nausea (35 events), headache (20 events), vomiting (18 events) and diarrhoea (8 events).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a placebo-controlled, parallel-group, subject- and investigator-blind study of LY in subjects (N = 43) with type 2 diabetes mellitus controlled with diet and exercise alone or with a single oral antidiabetic medication.
Summary · context
Subjects received five once-weekly doses of 0.05, 0.3, 1, 3, 5 or 8 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2125117809
10HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialSafety outcome
In a placebo-controlled study of LY in patients with type 2 diabetes, vomiting was among the most commonly reported adverse effects, with 18 events.
In plain wordsIn a study of LY in people with type 2 diabetes, 18 vomiting events were reported.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableVomiting
Study
n = 43
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Vomiting events
18 events
all reported events in the study
Source sentences
Summary
The most commonly reported adverse effects (AEs) were nausea (35 events), headache (20 events), vomiting (18 events) and diarrhoea (8 events).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a placebo-controlled, parallel-group, subject- and investigator-blind study of LY in subjects (N = 43) with type 2 diabetes mellitus controlled with diet and exercise alone or with a single oral antidiabetic medication.
Summary · context
Subjects received five once-weekly doses of 0.05, 0.3, 1, 3, 5 or 8 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2125117810
11HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialSafety outcome
In a placebo-controlled study of LY in patients with type 2 diabetes, diarrhoea was among the most commonly reported adverse effects, with 8 events.
In plain wordsIn a study of LY in people with type 2 diabetes, 8 diarrhoea events were reported.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDiarrhoea
Study
n = 43
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Diarrhoea events
8 events
all reported events in the study
Source sentences
Summary
The most commonly reported adverse effects (AEs) were nausea (35 events), headache (20 events), vomiting (18 events) and diarrhoea (8 events).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a placebo-controlled, parallel-group, subject- and investigator-blind study of LY in subjects (N = 43) with type 2 diabetes mellitus controlled with diet and exercise alone or with a single oral antidiabetic medication.
Summary · context
Subjects received five once-weekly doses of 0.05, 0.3, 1, 3, 5 or 8 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2125117811

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT05459285

A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects

Sunshine Lake Pharma Co., Ltd.n = 6831 May 2022 to 8 Jul 2022

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 25 Aug 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.